Escient Pharmaceuticals Inc.

Incyte Corporation sees potential in Escient Pharmaceuticals Inc. ’s MRGPR X2 and X4 antagonists to augment ongoing programs in its pipeline and to begin generating revenue at about the same time th

Novartis AG and Roche Holding AG ’s Xolair (omalizumab) has held a monopoly in chronic spontaneous urticaria for some years. Now, though, another agent might end Xolair’s solo reign: Novartis’s own

The end of each year brings a surge in venture capital funding announcements as biopharmaceutical companies and investors seek to close as many deals as possible before everyone takes off for the Dece

Neogene Therapeutics, Inc. , with a $110m series A venture capital round, led a group of five biopharmaceutical companies that revealed $320m in significant VC financings on a single day. The New York